Clinical significance of PD-L1 expression in brain metastases from non-small cell lung cancer

Shinkichi Takamori, Gouji Toyokawa, Isamu Okamoto, Kazuki Takada, Fumihiko Kinoshita, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Takaki Akamine, Nobutaka Mukae, Fumihiko Hirai, Tetsuzo Tagawa, Yoshinao Oda, Toru Iwaki, Koji Iihara, Yoichi Nakanishi, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿記事

5 引用 (Scopus)

抄録

Aim: To investigate the association between positivity for programmed cell death-ligand 1 (PD-L1) in brain metastases (BM) and the prognosis or clinical factors in patients with non-small cell lung cancer (NSCLC). Materials and Methods: Thirty-two patients with surgically resected brain-metastatic NSCLC were enrolled. The PD-L1 expression in BM was analyzed using the antibody against human PD-L1 (clone SP142). The PD-L1 positivity was defined as PD-L1 expression on brain-metastatic tumor cells of =5%. Results: Seven (21.9%) out of 32 patients showed PD-L1 positivity in BM. The PD-L1-positive BM group had a significantly shorter brain-specific disease-free survival than the PD-L1-negative BM group (p<0.05). PD-L1 positivity in BM was significantly associated with a heavy smoking history and the administration of radiotherapy for BM before surgery (p<0.05 and p<0.05, respectively). Conclusion: The PD-L1 expression in BM from NSCLC may be associated with local recurrence following surgery, and the smoking- or radiotherapy-derived effects.

元の言語英語
ページ(範囲)553-557
ページ数5
ジャーナルAnticancer research
38
発行部数1
DOI
出版物ステータス出版済み - 1 1 2018

Fingerprint

Non-Small Cell Lung Carcinoma
Cell Death
Neoplasm Metastasis
Ligands
Brain
Radiotherapy
Smoking
Brain Diseases
Brain Neoplasms
Disease-Free Survival
Clone Cells
History
Recurrence
Antibodies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Takamori, S., Toyokawa, G., Okamoto, I., Takada, K., Kinoshita, F., Kozuma, Y., ... Maehara, Y. (2018). Clinical significance of PD-L1 expression in brain metastases from non-small cell lung cancer. Anticancer research, 38(1), 553-557. https://doi.org/10.21873/anticanres.12258

Clinical significance of PD-L1 expression in brain metastases from non-small cell lung cancer. / Takamori, Shinkichi; Toyokawa, Gouji; Okamoto, Isamu; Takada, Kazuki; Kinoshita, Fumihiko; Kozuma, Yuka; Matsubara, Taichi; Haratake, Naoki; Akamine, Takaki; Mukae, Nobutaka; Hirai, Fumihiko; Tagawa, Tetsuzo; Oda, Yoshinao; Iwaki, Toru; Iihara, Koji; Nakanishi, Yoichi; Maehara, Yoshihiko.

:: Anticancer research, 巻 38, 番号 1, 01.01.2018, p. 553-557.

研究成果: ジャーナルへの寄稿記事

Takamori, S, Toyokawa, G, Okamoto, I, Takada, K, Kinoshita, F, Kozuma, Y, Matsubara, T, Haratake, N, Akamine, T, Mukae, N, Hirai, F, Tagawa, T, Oda, Y, Iwaki, T, Iihara, K, Nakanishi, Y & Maehara, Y 2018, 'Clinical significance of PD-L1 expression in brain metastases from non-small cell lung cancer', Anticancer research, 巻. 38, 番号 1, pp. 553-557. https://doi.org/10.21873/anticanres.12258
Takamori, Shinkichi ; Toyokawa, Gouji ; Okamoto, Isamu ; Takada, Kazuki ; Kinoshita, Fumihiko ; Kozuma, Yuka ; Matsubara, Taichi ; Haratake, Naoki ; Akamine, Takaki ; Mukae, Nobutaka ; Hirai, Fumihiko ; Tagawa, Tetsuzo ; Oda, Yoshinao ; Iwaki, Toru ; Iihara, Koji ; Nakanishi, Yoichi ; Maehara, Yoshihiko. / Clinical significance of PD-L1 expression in brain metastases from non-small cell lung cancer. :: Anticancer research. 2018 ; 巻 38, 番号 1. pp. 553-557.
@article{e387dd5b66b64823a4f67a7f7fbc4b1c,
title = "Clinical significance of PD-L1 expression in brain metastases from non-small cell lung cancer",
abstract = "Aim: To investigate the association between positivity for programmed cell death-ligand 1 (PD-L1) in brain metastases (BM) and the prognosis or clinical factors in patients with non-small cell lung cancer (NSCLC). Materials and Methods: Thirty-two patients with surgically resected brain-metastatic NSCLC were enrolled. The PD-L1 expression in BM was analyzed using the antibody against human PD-L1 (clone SP142). The PD-L1 positivity was defined as PD-L1 expression on brain-metastatic tumor cells of =5{\%}. Results: Seven (21.9{\%}) out of 32 patients showed PD-L1 positivity in BM. The PD-L1-positive BM group had a significantly shorter brain-specific disease-free survival than the PD-L1-negative BM group (p<0.05). PD-L1 positivity in BM was significantly associated with a heavy smoking history and the administration of radiotherapy for BM before surgery (p<0.05 and p<0.05, respectively). Conclusion: The PD-L1 expression in BM from NSCLC may be associated with local recurrence following surgery, and the smoking- or radiotherapy-derived effects.",
author = "Shinkichi Takamori and Gouji Toyokawa and Isamu Okamoto and Kazuki Takada and Fumihiko Kinoshita and Yuka Kozuma and Taichi Matsubara and Naoki Haratake and Takaki Akamine and Nobutaka Mukae and Fumihiko Hirai and Tetsuzo Tagawa and Yoshinao Oda and Toru Iwaki and Koji Iihara and Yoichi Nakanishi and Yoshihiko Maehara",
year = "2018",
month = "1",
day = "1",
doi = "10.21873/anticanres.12258",
language = "English",
volume = "38",
pages = "553--557",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Clinical significance of PD-L1 expression in brain metastases from non-small cell lung cancer

AU - Takamori, Shinkichi

AU - Toyokawa, Gouji

AU - Okamoto, Isamu

AU - Takada, Kazuki

AU - Kinoshita, Fumihiko

AU - Kozuma, Yuka

AU - Matsubara, Taichi

AU - Haratake, Naoki

AU - Akamine, Takaki

AU - Mukae, Nobutaka

AU - Hirai, Fumihiko

AU - Tagawa, Tetsuzo

AU - Oda, Yoshinao

AU - Iwaki, Toru

AU - Iihara, Koji

AU - Nakanishi, Yoichi

AU - Maehara, Yoshihiko

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Aim: To investigate the association between positivity for programmed cell death-ligand 1 (PD-L1) in brain metastases (BM) and the prognosis or clinical factors in patients with non-small cell lung cancer (NSCLC). Materials and Methods: Thirty-two patients with surgically resected brain-metastatic NSCLC were enrolled. The PD-L1 expression in BM was analyzed using the antibody against human PD-L1 (clone SP142). The PD-L1 positivity was defined as PD-L1 expression on brain-metastatic tumor cells of =5%. Results: Seven (21.9%) out of 32 patients showed PD-L1 positivity in BM. The PD-L1-positive BM group had a significantly shorter brain-specific disease-free survival than the PD-L1-negative BM group (p<0.05). PD-L1 positivity in BM was significantly associated with a heavy smoking history and the administration of radiotherapy for BM before surgery (p<0.05 and p<0.05, respectively). Conclusion: The PD-L1 expression in BM from NSCLC may be associated with local recurrence following surgery, and the smoking- or radiotherapy-derived effects.

AB - Aim: To investigate the association between positivity for programmed cell death-ligand 1 (PD-L1) in brain metastases (BM) and the prognosis or clinical factors in patients with non-small cell lung cancer (NSCLC). Materials and Methods: Thirty-two patients with surgically resected brain-metastatic NSCLC were enrolled. The PD-L1 expression in BM was analyzed using the antibody against human PD-L1 (clone SP142). The PD-L1 positivity was defined as PD-L1 expression on brain-metastatic tumor cells of =5%. Results: Seven (21.9%) out of 32 patients showed PD-L1 positivity in BM. The PD-L1-positive BM group had a significantly shorter brain-specific disease-free survival than the PD-L1-negative BM group (p<0.05). PD-L1 positivity in BM was significantly associated with a heavy smoking history and the administration of radiotherapy for BM before surgery (p<0.05 and p<0.05, respectively). Conclusion: The PD-L1 expression in BM from NSCLC may be associated with local recurrence following surgery, and the smoking- or radiotherapy-derived effects.

UR - http://www.scopus.com/inward/record.url?scp=85039775322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039775322&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12258

DO - 10.21873/anticanres.12258

M3 - Article

VL - 38

SP - 553

EP - 557

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -